Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market to Witness Significant Growth of USD $2.01 Billion with 9.9% CAGR by 2030

The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

What Is the Estimated Market Growth Potential of the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market by 2030?
The vesicular monoamine transporter 2 (vmat2) inhibitor market size has grown rapidly in recent years. It will grow from $1.25 billion in 2025 to $1.37 billion in 2026 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to approval of tetrabenazine, rising antipsychotic usage, increased movement disorder diagnosis, hospital-based neurology care, limited alternative therapies.

The vesicular monoamine transporter 2 (vmat2) inhibitor market size is expected to see strong growth in the next few years. It will grow to $2.01 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to growing tardive dyskinesia prevalence, expansion of deutetrabenazine usage, rising neurological disorder awareness, growth of specialty neurology clinics, increased oral drug preference. Major trends in the forecast period include rising use of targeted neurotransmitter modulation, increasing treatment of tardive dyskinesia, expansion of oral neurological therapies, growing focus on movement disorder management, increased adoption of long-term neurology drugs.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/vesicular-monoamine-transporter-2-vmat2-inhibitor-global-market-report

What Are the Key Factors Contributing to Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Growth?
The increasing prevalence of parkinson’s disease is expected to propel the growth of the vesicular monoamine transporter 2 (VMAT2) inhibitor market going forward. Parkinson's disease refers to a progressive neurological disorder that affects movement due to the loss of dopamine-producing cells in the brain. The increasing prevalence of parkinson's disease is mainly due to an aging population, better diagnosis, environmental factors such as toxins, genetic influences, and greater awareness of the condition. VMAT2 inhibitors help manage Parkinson's symptoms by controlling dopamine release and reducing tremors and dyskinesia. For instance, in October 2025, according to the Parkinson's UK, a UK-based research and support charity, by 2030, Parkinson’s cases in the UK are expected to reach 173,000, and around 28,000 people are projected to be diagnosed in 2025, which means one new diagnosis every 20 minutes as the population grows and ages. Therefore, the increased prevalence of Parkinson’s disease is driving growth in the vesicular monoamine transporter 2 (VMAT2) inhibitor market.

What Segments Are Covered in the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Report?
The vesicular monoamine transporter 2 (vmat2) inhibitor market covered in this report is segmented –

1) By Drugs: Tetrabenazine, Deutetrabenazine, Valbenazine, Other Drugs
2) By Route Of Administration: Oral, Other Administrations
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By Application: Huntington’s Disease, Tardive Dyskinesia, Other Applications
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Tetrabenazine: Huntington’s Disease Treatment, Tardive Dyskinesia Management, Tourette Syndrome Treatment
2) By Deutetrabenazine: Huntington’s Disease Chorea, Tardive Dyskinesia Treatment, Off-Label Movement Disorders
3) By Valbenazine: Tardive Dyskinesia Treatment, Tourette Syndrome Research, Other Hyperkinetic Movement Disorders
4) By Other Drugs: Investigational VMAT2 Inhibitors, Emerging Therapies For Movement Disorders, Off-Label Use In Neurological Conditions

Which Trends Are Expected to Redefine the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Landscape?
Major companies operating in the vesicular monoamine transporter 2 (VMAT2) inhibitors market are focusing on developing innovative formulations such as capsules to enhance patient compliance, improve drug stability, and optimize therapeutic efficacy. Capsules, a solid dosage form enclosed in a gelatin or HPMC shell, help VMAT2 inhibitors by improving drug stability, ensuring precise dosing, and enhancing patient compliance. For instance, in July 2024, Neurocrine Biosciences Inc., a US-based biopharmaceutical company, launched Ingrezza Sprinkle (valbenazine) capsules, a new formulation of the VMAT2 inhibitor Ingrezza designed to ease administration for adults with tardive dyskinesia and chorea associated with Huntington's disease who experience dysphagia or difficulty swallowing. Ingrezza Sprinkle offers the same effective dosing options as Ingrezza and can be administered by sprinkling the contents of the capsule onto soft food or by swallowing the capsule whole.

Who Are the Top Competitors in the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market?
Major companies operating in the vesicular monoamine transporter 2 (vmat2) inhibitor market are Neurocrine Biosciences Inc., H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Bausch Health Companies Inc., Luye Pharma Group Ltd., Mitsubishi Tanabe Pharma Corporation, Sumitomo Dainippon Pharma, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Eli Lilly and Company, Merck KGaA, Johnson & Johnson, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Biogen Inc

Get the full vesicular monoamine transporter 2 (vmat2) inhibitor market report here:
https://www.thebusinessresearchcompany.com/report/vesicular-monoamine-transporter-2-vmat2-inhibitor-global-market-report

Which Region Is Expected to Lead the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market by 2030?
North America was the largest region in the vesicular monoamine transporter 2 (VMAT2) inhibitor market in 2025. The regions covered in the vesicular monoamine transporter 2 (vmat2) inhibitor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn